当社CMC開発部・栁谷が核酸医薬・ペプチド医薬に係る国際会議TIDES ASIA 2024にてポスター発表と座長（セッションチェア）を務めます。ぜひお立ち寄りください。

【学会概要】TIDES ASIA
　TIDES Asia: Oligonucleotide & Peptide Therapeutics (informaconnect.com)
【開催日時場所】2024年3月19日～21日　 日本 京都府　ウェスティン都ホテル京都
【ポスタートピック】RNA Therapeutics and Vaccines
【会場ポスター番号】 23
【参照番号】TIDESASIA24_18_Yanagiya
【ポスター掲示期間】Tuesday, March 20th: 11:00AM-2:00PM JST      
【概要】
ARCALIS was established as a CDMO for mRNA vaccine and therapeutics, which have emerged as practical clinical applications recent years. ARCALIS has provided customers with seamless services from mRNA therapeutics development to large-scale manufacturing. Our drug substance plant was launched to manufacture mRNA medicine in Minami-Soma, Fukushima in 2023, in which a drug product plant to manufacture mRNA-LNP and a MD plant to manufacture template DNA will be constructed in 2026 and 2027, respectively.
Kostaive was approved in Japan as a self-amplifying mRNA (saRNA) for COVID-19 vaccine for the first time in the world, which is manufactured in ARCALIS’s Minami-Soma plant.
ARCALIS also provides innovative mRNA design by our original codon optimization algorithms along with unique 5’ and 3’ UTRs for efficient protein expression according to the customers’ needs. In collaboration with ADDP, ARCALIS evaluates mRNA potencies by in vivo/vitro experiments.
◎　Akiko Yanagiya, Rena Akahori, Hiroaki Murakami, Azusa Tanaka, Yanwen Feng, Hayato Sato, Naoki Matsumoto, Daichi Matsuura, Jun Nihira, Tetsuo Yoshida, Yuki Hasegawa, Kazuyuki Nakashima

【座長】
Track #1
Wednesday 21st: 10:55AM-12:30 PM JST
Track #1
Wednesday 21st: 13:30PM-15:05 PM JST
Track #1
Wednesday 21st: 15:35PM-17:05 PM JST